Rostec to Create Proton Cancer Therapy Center in Kaluga Region by 2024

| By | Cancer therapy, Rostec
0
150

Ruselectronics Holding (integrated with the state corporation Rostec) in conjunction with the Health Ministry’s National Research Radiological Center and the Czech company Proton Therapy Development s.r.o. will create a proton cancer therapy center in the Kaluga region. The center will be set up in Obninsk by 2024, Rostec reported.

Investment in the project amounts to about 12 billion rubles ($150m). The project will be operated by Vega Radio-Engineering Concern (integrated with Ruselectronics) and co-funded by Proton Therapy Development s.r.o.

The trilateral cooperation agreement was signed at the St. Petersburg international economic forum on Friday by Vega General Director Vyacheslav Mikheyev, General Director of the National Research Radiological Center Andrei Kaprin and Proton Therapy Development s.r.o. head Ludek Padola.

Rostec and the partners are working to create proton cancer therapy centers in order to make the most advanced methods of treating cancer more accessible to Russian patients. One of the world’s leading proton therapy clinics is located in Prague, therefore our Czech colleagues’ experience is important, Rostec head Sergei Chemezov was quoted as saying.

Rostec sees this branch of cancer care as very promising given that it will be included in the program of insurance-covered high technology healthcare from 2020. The creation of proton cancer therapy centers ranks among Rostec’s key targets under the national healthcare project. The state corporation is building such centers in Moscow, in Primorye, in Novosibirsk and in Obninsk.

JSC Vega Radio Engineering Concern was formed in 2004 and is the head company of Ruselectronics’ intelligence information systems division which develops and makes a wide spectrum of innovative radioelectronics products, and military-purpose and civilian systems.
Proton Therapy Development s.r.o. is the management company of the Prague proton therapy center. It was formed in 2012 and treats up to 2,500 patients, annually.

SOURCE: interfax.ru
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.